I-MabNASDAQ:IMAB
- LAST PRICE1.2400
- TODAY'S CHANGE (%)0.0900 (7.8261%)
- Bid / Lots1.2000/ 10
- Ask / Lots1.2500/ 15
- Open / Previous Close1.1700 / 1.1500
- Day Range
- 52 Week Range
- Volume490,935
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMAB |
|---|---|---|
| 09:32 ET | 9232 | 1.17 |
| 09:34 ET | 9419 | 1.17 |
| 09:36 ET | 4981 | 1.17 |
| 09:38 ET | 300 | 1.17 |
| 09:39 ET | 1090 | 1.1704 |
| 09:41 ET | 500 | 1.175 |
| 09:43 ET | 700 | 1.175 |
| 09:45 ET | 2556 | 1.1797 |
| 09:48 ET | 2200 | 1.1793 |
| 09:50 ET | 8662 | 1.17 |
| 09:52 ET | 1587 | 1.1688 |
| 09:54 ET | 1079 | 1.165 |
| 09:56 ET | 900 | 1.165 |
| 09:57 ET | 1800 | 1.16 |
| 09:59 ET | 8400 | 1.16 |
| 10:01 ET | 100 | 1.16 |
| 10:03 ET | 2000 | 1.15 |
| 10:08 ET | 11504 | 1.15 |
| 10:10 ET | 2004 | 1.15 |
| 10:12 ET | 240 | 1.1511 |
| 10:14 ET | 896 | 1.15 |
| 10:15 ET | 1200 | 1.15 |
| 10:17 ET | 510 | 1.155 |
| 10:19 ET | 2536 | 1.15 |
| 10:21 ET | 15534 | 1.15 |
| 10:24 ET | 1030 | 1.156745 |
| 10:26 ET | 1300 | 1.15 |
| 10:28 ET | 5702 | 1.14 |
| 10:30 ET | 10660 | 1.13 |
| 10:32 ET | 22034 | 1.13 |
| 10:35 ET | 1758 | 1.14 |
| 10:37 ET | 21448 | 1.16 |
| 10:39 ET | 527 | 1.1698 |
| 10:42 ET | 3140 | 1.175 |
| 10:44 ET | 2573 | 1.175 |
| 10:46 ET | 1838 | 1.18 |
| 10:48 ET | 600 | 1.185 |
| 10:50 ET | 100 | 1.1804 |
| 10:51 ET | 3100 | 1.1805 |
| 10:53 ET | 100 | 1.19 |
| 10:55 ET | 134 | 1.1804 |
| 10:57 ET | 4030 | 1.1971 |
| 11:02 ET | 1786 | 1.2 |
| 11:04 ET | 22116 | 1.205 |
| 11:06 ET | 4728 | 1.2 |
| 11:08 ET | 1290 | 1.2 |
| 11:09 ET | 620 | 1.205 |
| 11:11 ET | 11864 | 1.2 |
| 11:13 ET | 929 | 1.21 |
| 11:15 ET | 444 | 1.2096 |
| 11:18 ET | 11865 | 1.2005 |
| 11:20 ET | 200 | 1.2 |
| 11:24 ET | 3356 | 1.2 |
| 11:26 ET | 100 | 1.2004 |
| 11:29 ET | 1787 | 1.2 |
| 11:31 ET | 3000 | 1.2006 |
| 11:33 ET | 11578 | 1.195 |
| 11:36 ET | 2200 | 1.19 |
| 11:42 ET | 536 | 1.1901 |
| 11:47 ET | 4127 | 1.19 |
| 11:49 ET | 100 | 1.1904 |
| 11:51 ET | 168 | 1.195 |
| 11:58 ET | 150 | 1.1903 |
| 12:02 ET | 100 | 1.195 |
| 12:05 ET | 7868 | 1.19 |
| 12:07 ET | 3024 | 1.19 |
| 12:09 ET | 750 | 1.1987 |
| 12:12 ET | 1620 | 1.185 |
| 12:21 ET | 200 | 1.185 |
| 12:32 ET | 781 | 1.19 |
| 12:34 ET | 1100 | 1.19 |
| 12:39 ET | 670 | 1.1888 |
| 12:45 ET | 150 | 1.1804 |
| 12:48 ET | 3100 | 1.181 |
| 12:50 ET | 400 | 1.18 |
| 12:52 ET | 429 | 1.1801 |
| 12:54 ET | 100 | 1.19 |
| 12:56 ET | 10000 | 1.19 |
| 12:59 ET | 100 | 1.19 |
| 01:01 ET | 2000 | 1.19 |
| 01:06 ET | 200 | 1.185 |
| 01:08 ET | 200 | 1.185 |
| 01:10 ET | 10800 | 1.19 |
| 01:12 ET | 8680 | 1.2 |
| 01:14 ET | 100 | 1.205 |
| 01:15 ET | 700 | 1.205 |
| 01:17 ET | 436 | 1.2096 |
| 01:19 ET | 3716 | 1.21 |
| 01:21 ET | 100 | 1.22 |
| 01:24 ET | 5500 | 1.2162 |
| 01:26 ET | 500 | 1.215 |
| 01:30 ET | 400 | 1.215 |
| 01:33 ET | 200 | 1.22 |
| 01:35 ET | 200 | 1.2185 |
| 01:37 ET | 5000 | 1.22 |
| 01:42 ET | 3100 | 1.2101 |
| 01:44 ET | 100 | 1.22 |
| 01:50 ET | 100 | 1.22 |
| 01:53 ET | 2381 | 1.22 |
| 01:55 ET | 195 | 1.2104 |
| 01:57 ET | 5104 | 1.22 |
| 02:00 ET | 100 | 1.215 |
| 02:02 ET | 18416 | 1.23 |
| 02:04 ET | 2200 | 1.22 |
| 02:06 ET | 2300 | 1.22 |
| 02:20 ET | 3211 | 1.22 |
| 02:22 ET | 100 | 1.22 |
| 02:24 ET | 1900 | 1.21 |
| 02:27 ET | 1621 | 1.23 |
| 02:29 ET | 2181 | 1.2245 |
| 02:33 ET | 3000 | 1.22 |
| 02:36 ET | 586 | 1.2296 |
| 02:38 ET | 1075 | 1.225 |
| 02:40 ET | 3117 | 1.2204 |
| 02:42 ET | 1900 | 1.22 |
| 02:44 ET | 3232 | 1.23 |
| 02:45 ET | 2000 | 1.231317 |
| 02:47 ET | 5634 | 1.24 |
| 02:49 ET | 200 | 1.235 |
| 02:51 ET | 6241 | 1.235 |
| 02:54 ET | 213 | 1.2304 |
| 02:58 ET | 1600 | 1.235 |
| 03:00 ET | 974 | 1.2301 |
| 03:02 ET | 3186 | 1.23 |
| 03:03 ET | 976 | 1.24 |
| 03:05 ET | 800 | 1.2323 |
| 03:07 ET | 420 | 1.24 |
| 03:09 ET | 206 | 1.2314 |
| 03:12 ET | 274 | 1.2396 |
| 03:14 ET | 2700 | 1.23 |
| 03:16 ET | 1100 | 1.23 |
| 03:18 ET | 600 | 1.225 |
| 03:20 ET | 100 | 1.23 |
| 03:21 ET | 2300 | 1.225 |
| 03:23 ET | 3010 | 1.23 |
| 03:25 ET | 200 | 1.225 |
| 03:27 ET | 100 | 1.225 |
| 03:30 ET | 9742 | 1.2242 |
| 03:38 ET | 1596 | 1.22 |
| 03:39 ET | 2587 | 1.22 |
| 03:41 ET | 1000 | 1.225 |
| 03:45 ET | 2593 | 1.22 |
| 03:48 ET | 9200 | 1.23 |
| 03:50 ET | 714 | 1.2215 |
| 03:52 ET | 400 | 1.235 |
| 03:54 ET | 10320 | 1.2311 |
| 03:56 ET | 6259 | 1.235 |
| 03:57 ET | 6470 | 1.2399 |
| 03:59 ET | 13249 | 1.24 |
Sep 17, 2024
DJ I-Mab Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 7:40AM ET on Tuesday Sep 17, 2024 by Dow Jones
7:40AM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 16, 2024
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024, from 4:01PM ET on Monday Sep 16, 2024 by Dow Jones
4:01PM ET on Monday Sep 16, 2024 by Dow Jones
Sep 10, 2024
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer, from 7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
I-Mab | 85.7M | 0.0x | --- |
Verrica Pharmaceuticals Inc | 84.1M | -0.8x | --- |
Zhong Yuan Bio-Technology Holdings Ltd | 88.2M | 391.4x | --- |
Cellectar Biosciences Inc | 76.4M | -0.7x | --- |
Spectral Medical Inc | 138.8M | -9.2x | --- |
Hongchang International Co Ltd | 129.7M | -450.0x | --- |
Company Information
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Contact Information
- Headquarters
- Suite 400, 2440 Research BlvdROCKVILLE, MD, United States 20850
- Phone
- 301-670-2800
- Fax
- ---
Executives
- Chairman of the Board
- Wei Fu
- Interim Chief Executive Officer, Director
- Xi-Yong Fu
- Chief Financial Officer
- Joseph Skelton
- Chief Medical Officer
- Phillip Dennis
- Director
- Shuai Chen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $85.7M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 80.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.07 |
EPS | --- |
Book Value | $3.00 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
